Navigating the Complexities of Next-Generatio...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Up next

'No Margin for Error': What to Know Before Implementing AI in Clinical Practice

Dr. Monty Pal and Dr. Arturo Loaiza-Bonilla discuss the institutional risks in the use of artificial intelligence (AI) in clinical practice and how overreliance on AI could erode essential skills. They also highlight practical approaches, including routine "AI-off" drills, to hel ... Show more

. 18min 20sec

Groundbreaking Results Shift Treatment Paradigm in High-Risk Smoldering Multiple Myeloma

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Mo ... Show more

. 19min 38sec

Recommended Episodes

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update

ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show more

. 14min 9sec

Systemic Therapy for Advanced HER2-Positive Breast Cancer Guideline Update

ASCO Guidelines

An interview with Dr. Sharon Giordano from the University of Texas MD Anderson Cancer Center in Houston, TX, and Dr. Nancy Davidson from Fred Hutchinson Cancer Research Center and the University of Washington in Seattle, WA, co-chairs on "Systemic Therapy for Advanced HER2-Positi ... Show more

. 13min 34sec

Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Rapid Recommendation Update

ASCO Guidelines

Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, and presents treatment recommendatio ... Show more

. 10min 42sec

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update

ASCO Guidelines

Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive HER2-negative metastatic breast cancer based on recent evidence published in TROPiCS-02. ... Show more

. 7min 7sec